» Articles » PMID: 28626809

Epidermal Growth Factor Prevents -induced Cognitive and Cerebrovascular Deficits in Female Mice

Overview
Journal Heliyon
Specialty Social Sciences
Date 2017 Jun 20
PMID 28626809
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Cerebrovascular dysfunction is re-emerging as a major component of aging, and may contribute to the risk of developing Alzheimer's disease (AD). Two important risk factors for cerebrovascular dysfunction are and female sex, which are primarily researched in the context of high amyloid-β (Aβ) levels as found in AD. However, and sex modulate Aβ-independent pathways that may induce cerebrovascular dysfunction as a downstream consequence. Therefore, testing the activity of factors that target cerebrovascular dysfunction in Aβ-independent models that incorporate and female sex is crucial. We have previously demonstrated that peripheral administration of the epidermal growth factor (EGF) prevents cognitive dysfunction, cerebrovascular leakiness, and cerebrovascular coverage deficits in female mice that express and overproduce Aβ, without affecting Aβ levels. These data raise the question of whether EGF protects the cerebrovasculature from general stress-induced damage. Therefore, the goal of this study was to determine whether EGF prevents Aβ-independent cerebrovascular dysfunction. In eight-month old mice that express human , the interaction of and female sex induced cognitive dysfunction, increased cerebrovascular leakiness and lowered vessel coverage. Importantly, in a prevention paradigm (from six to eight and a half months of age), EGF ameliorated cognitive decline and cerebrovascular deficits in female mice that express . Thus, developing treatment strategies based on EGF signaling could provide alternative therapeutic options for age-related cerebrovascular dysfunction and reduce AD risk.

Citing Articles

Alzheimer's disease and infectious agents: a comprehensive review of pathogenic mechanisms and microRNA roles.

Hosseininasab S, Ebrahimi R, Yaghoobpoor S, Kazemi K, Khakpour Y, Hajibeygi R Front Neurosci. 2025; 18():1513095.

PMID: 39840010 PMC: 11747386. DOI: 10.3389/fnins.2024.1513095.


Apolipoprotein E polymorphisms and female fertility in a transgenic mouse model of Alzheimer's disease.

Medegan Fagla B, York J, Christensen A, Dela Rosa C, Balu D, Pike C Sci Rep. 2024; 14(1):15873.

PMID: 38982272 PMC: 11233746. DOI: 10.1038/s41598-024-66489-w.


Estradiol improves behavior in FAD transgenic mice that express but not after ovariectomy.

Balu D, Valencia-Olvera A, Deshpande A, Narayanam S, Konasani S, Pattisapu S Front Endocrinol (Lausanne). 2024; 15:1374825.

PMID: 38742194 PMC: 11089251. DOI: 10.3389/fendo.2024.1374825.


A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3.

Valencia-Olvera A, Balu D, Bellur S, McNally T, Saleh Y, Pham D Alzheimers Res Ther. 2023; 15(1):216.

PMID: 38102668 PMC: 10722727. DOI: 10.1186/s13195-023-01353-z.


genotype and sex modulate Alzheimer's disease pathology in aged EFAD transgenic mice.

Balu D, Valencia-Olvera A, Islam Z, Mielczarek C, Hansen A, Perez Ramos T Front Aging Neurosci. 2023; 15:1279343.

PMID: 38020764 PMC: 10644540. DOI: 10.3389/fnagi.2023.1279343.


References
1.
Siddiqui S, Fang M, Ni B, Lu D, Martin B, Maudsley S . Central role of the EGF receptor in neurometabolic aging. Int J Endocrinol. 2012; 2012:739428. PMC: 3382947. DOI: 10.1155/2012/739428. View

2.
Tang Y, Ye M, Du Y, Qiu X, Lv X, Yang W . EGFR signaling upregulates surface expression of the GluN2B-containing NMDA receptor and contributes to long-term potentiation in the hippocampus. Neuroscience. 2015; 304:109-21. DOI: 10.1016/j.neuroscience.2015.07.021. View

3.
Bour A, Grootendorst J, Vogel E, Kelche C, Dodart J, Bales K . Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav Brain Res. 2008; 193(2):174-82. DOI: 10.1016/j.bbr.2008.05.008. View

4.
Grammas P, Martinez J, Sanchez A, Yin X, Riley J, Gay D . A new paradigm for the treatment of Alzheimer's disease: targeting vascular activation. J Alzheimers Dis. 2014; 40(3):619-30. DOI: 10.3233/JAD-2014-132057. View

5.
van de Haar H, Burgmans S, Hofman P, Verhey F, Jansen J, Backes W . Blood-brain barrier impairment in dementia: current and future in vivo assessments. Neurosci Biobehav Rev. 2014; 49:71-81. DOI: 10.1016/j.neubiorev.2014.11.022. View